April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like ...

Researchers predict a steady increase in fatty liver disease in the U.S. population, but there's not a lot of treatment ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were ...

The addition of multiparametric MRI to standard of care was cost-effective and enhanced diagnosis rates among patients with ...

They cite previous analyses showing that 38% of adults in North America or Australia had MASLD by 2019, and that 5% had metabolic dysfunction-associated steatohepatitis (MASH), previously known as ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...